Rapport Therapeutics, Inc. (RAPP) — Stock Score Summary

Rapport Therapeutics, Inc. (RAPP) has a MoatMap StockRank of 49/100 based on Quality (39/100), Value (36/100), and Momentum (61/100) factor scores. The current signal is HOLD. Rapport Therapeutics is an early-stage clinical biotechnology company that lacks the established cash flows, high ROIC, and structural moat required by our quality compounding lens.

Rapport Therapeutics, Inc. is a biotechnology company focused on developing precision medicines for neurological disorders by leveraging its platform to selectively modulate ion channels. The company's approach aims to create highly targeted therapies that minimize off-target effects, addressing significant unmet needs in conditions like epilepsy and neuropathic pain. Its innovative platform and focus on specific ion channel pharmacology represent a strong, specialized competitive position in neuroscience drug development.

Key Financial Metrics

Price$35.84
Market Cap$1.9B
P/E (Forward)-8.39
Price/Book3.80
Return on Equity-28.3%
Return on Invested Capital-25.4%
Debt/Equity2.29
Gross Margin34.3%
Operating Margin-121.1%
Free Cash Flow$-49M

Rapport Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Rapport Therapeutics, Inc.’s (RAPP) StockRank?
MoatMap’s StockRank for Rapport Therapeutics, Inc. (RAPP) is 49/100, with a Hold signal. It is a composite of Quality (39), Value (36), and Momentum (61) factor ranks across MoatMap’s 19,000+ stock universe.
Does Rapport Therapeutics, Inc. have an economic moat?
Rapport Therapeutics, Inc. (RAPP) has a Quality factor score of 39/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Rapport Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Rapport Therapeutics, Inc. (RAPP) is Hold, based on a StockRank of 49/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Rapport Therapeutics, Inc. in?
Rapport Therapeutics, Inc. (RAPP) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksRAPP deep dive reportAI ChampionsHow we score stocksSense-check another stock